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LANGERHANS CELLS FACILITATE MUTAGENESIS AND SQUAMOUS 
CELL CARCINOMA.  Badri G. Modi, Jason Neustadter, Julia Lewis, Renata Filler, 
Bernice Kwong, Swapna Reddy, Robert Tigelaar, Daniel Kaplan, Adrian Hayday, 
Michael Girardi. Department of Dermatology, Yale University, School of Medicine, New 
Haven, CT. 
 
Polyaromatic hydrocarbons (PAHs) are prevalent, potent carcinogens, and 7,12-
dimethylbenz[a]anthracene (DMBA) is a model PAH widely used to model epithelial 
carcinogenesis. To achieve mutagenic effects, DMBA must be activated to DMBA-trans-
3,4-diol via cytochrome p450 (CYP) 1B1, and this intermediate is the penultimate 
carcinogen responsible for inducing the signature mutation in the Hras oncogene. 
Recently, we observed that mice deficient in Langerhans cells (LCs), an epidermal 
dendritic cell (DC), are almost completely resistant to cutaneous chemical carcinogenesis, 
independent of αβ and γδ T cell influences. Investigations to identify the LC contribution 
to carcinogenesis revealed that DMBA-exposed LC-intact skin harbor more Hras 
mutations than LC-deficient skin, implying an early effect on tumor initiation. In vitro 
XS106 cells, a cell line derived from murine LCs, efficiently metabolized DMBA to 
DMBA-trans-3,4-diol as detected by liquid chromatography and tandem mass 
spectrometry. Moreover, initiation with DMBA-trans-3,4-diol bypassed tumor resistance 
and restored tumorigenesis in LC-deficient mice. Consistent with previous reports, 
murine and human LCs expressed a higher CYP1B1:CYP1A1 ratio than keratinocytes, 
conferring an advantage in the ability to metabolize to mutagenic intermediates. Thus, 
our data suggest a cooperative carcinogenesis scenario in which LC generate DMBA-
trans-3,4-diol which moves into keratinocytes for further metabolism and mutagenesis. 
Tissue-associated DCs – which are also found in other epithelial surfaces – can enhance 
chemical carcinogenesis via PAH metabolism, highlighting the complex relation between 
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I.  Introduction         
A.  EPITHELIAL TISSUES, CANCER, AND THE IMMUNE SYSTEM 
 Epithelial tissues are situated at critical junctures with the environment and serve 
as protective barriers from exogenous insults. Such epithelial linings have evolved an 
organizational structure in which the deepest layer of cells, often regarded as the basal 
layer and located adjacent to the basement membrane, are regenerative and supply the 
more superficial layers with differentiated cells that function in secretion, barrier 
protection, or other tissue specific roles [1]. In this dynamic process, the differentiated 
cells will ultimately be shed from the surface and replaced by a newly divided cell from 
the basal layer. With repeated environmental insults to epithelial tissues, perhaps this 
dynamic organizational structure evolved to enable clearing of damaged cells and 
maintenance of structural and functional integrity [2]. However, even this dynamic 
process frequently falls short of protecting epithelial surfaces from aberrant growth and 
tumorigenesis. In humans, more than ninety percent of neoplasms arise in epithelial 
tissues [3], which include the skin, gastrointestinal (GI), respiratory, and genitourinary 
(GU) tracts. The cutaneous epithelial surface (i.e. epidermis) is the site of the two most 
common human cancers [4] [5] – basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) – and accordingly offers a unique ability to model the biological events 
that contribute to carcinogenesis more generally. 
Many environmental factors are implicated in promoting the development of 
epithelial-derived tumors. For instance, ultraviolet light exposure is largely considered 
the major risk factor for cutaneous BCC and SCC. Similarly, polyaromatic hydrocarbons 




tumors. PAHs are ubiquitous chemicals in industrialized societies, present in automobile 
emissions, tobacco smoke, smoked foods, and ground water [1]. Accordingly, individuals 
exposed to occupational levels of PAHs experience up to 1.4 times the risk of lung cancer 
and 2.2 times the risk of bladder cancer compared to the normal population [6]. While 
perhaps not as important an environmental factor as UVR for the skin, PAHs have been 
shown to predispose mice to developing UVR-induced tumors. At doses at which neither 
induce tumors alone, the combination of UVR and PAHs results in a higher rate of 
tumorigenesis [7]. In addition, the reverse relationship also has been shown, where UV-
exposed mice are more sensitive to the PAH effects [8]. Due to its ability to induce 
tumors, PAHs serve as a means to model both environmental and non-environmental 
contributions to cancer through the chemical carcinogenesis protocol discussed below. 
 In addition to the organizational structure that helps to limit epithelial 
transformation, immune surveillance similarly is an important host protective 
phenomenon that helps to inhibit carcinogenesis. In support of this, organ transplant 
patient on immunosuppressive therapy are 65 to 250 times as likely to develop cutaneous 
squamous cell carcinoma than compared to the general population [9]. Consistent in non-
cutaneous epithelial sites, the risk of squamous cell carcinoma of the anal canal is 120 
times higher in HIV-positive patients compared to HIV-negative patients [10]. Several 
models demonstrate that mice lacking effector components of the immune system, 
including natural killer (NK) cells and natural killer T (NKT) cells, are more susceptible 
to PAH-induced tumors than their wild type counterparts [11]. Thus, clinical and 





Within the study of non-melanoma cutaneous cancer biology, several immune 
cells are implicated in affecting the development of tumors. Keratinocytes of the 
epidermis in mice are in close proximity to two distinct subsets of intraepithelial 
lymphocytes (IEL), namely the dendritic epidermal T cells (DETCs) [12] and the 
Langerhans cells (LCs). These two cell types form a network of intraepidermal immature 
immune cells and their dendritic processes extend to contact keratinocytes, including the 
epithelial stem cells in the basal layer and near hair follicles [1, 13].  
Girardi, Hayday, and Tigelaar have provided insight into the precise functions of 
the γδ DETC constituency of IELs. Mice lacking TCRδ(-/-) DETCs were highly 
susceptible to developing chemically-induced tumors compared to wild type mice, 
implying their role in the down-regulation of cutaneous malignancies [12, 14]. While αβ 
T cells predominantly circulate in the blood and lymphatics in systemic circulation until 
recruited to sites of inflammation, γδ DETC have been shown to down-regulate an over-
exuberant αβ T cell-mediated inflammatory response [12]. While these studies supported 
the role of γδ DETCs in regulating carcinogenesis, a similar mouse model of LC-
deficiency was not available to examine the role of the Langerhans cell in cutaneous 
carcinogenesis, until recently. 
 
B.  LANGERHANS CELLS BIOLOGY – THE PAST AND PRESENT 
 Our understanding of the Langerhans cell has evolved in many ways since 
identification in 1868. Paul Langerhans, a German medical student, mistakenly believed 
the dendritic processes to suggest he was observing distal nerve cells of the skin [15]. In 




regarded the cells as worn out, pigmentless melanocytes. Since then, key experiments 
have shifted our understanding of LC. In 1977, Stingle, Rowden, and Klareskog 
demonstrated the expression of Fc and complement receptors, and MHCII molecules on 
the LC surface, which cemented their classification as immune cells [16-19].  LC were 
found to migrate to the lymph node and have varying states of maturation based on 
location and antigen stimulation, suggesting a role in antigen presentation. Thus, the 
“Langerhans cell paradigm” developed and became the prototype for all tissue-resident 
tantigen presenting dendritic cells:  the life cycle consists of residing in the skin (or 
whichever specific tissue) until encountering an antigen, after which it migrates to a 
regional lymph node, and matures to upregulate surface molecules critical for 
presentation to T cells [16, 20].  
LC are derived from hematopoietic bone marrow cells [21], and the primary 
building block of Birbeck granules has been identified as langerin/CD207, a C-type lectin 
whose exact function is still unclear. The identification of CD207 has advanced the field 
of LC biology in two important ways [22]. First, it allows for antibody-mediated 
fluorescent tagging against CD207 which enabled visualization of the cells. Secondly, 
CD207 represented an LC-specific molecule that could serve as a target for the 
generation of an LC-deficient mouse model. 
One approach to depleting LC is the “huLangerin-DTA” (DTA) strategy and was 
developed by Dan Kaplan at Yale University. In this strategy, the active subunit of the 
diphtheria toxin is expressed under the control of the huLangerin promoter, which results 
in the selective ablation of epidermal langerin+, MHCII+ cells [23]. Along with other 




distinct populations of langerin+ skin cells – one localized to the epidermis and one 
localized to the dermis [24, 25]. With the advent of LC-deficient models, the 
understanding of LC-biology has further evolved and become more complex. Although 
the classic LC-paradigm would predict an LC-deficient mouse to develop a mitigated 
contact hypersensitivity (CHS) response, the LC-deficient DTA mouse model in fact 
developed a heightened CHS response as compared to wild type controls [23]. This and 
other data supported a role of LC in down-modulating the CHS response, while dermal 
langerin+ DC were important for stimulating the response [16, 22, 26].  
 
C.  LC-DEFICIENCY AND CHEMICAL CARCINOGENESIS 
 Similar to the predictions of the DTA mouse in the CHS experimental model, the 
classic LC-paradigm would expect the absence of an LC-mediated anti-tumor immune 
response. Just as tumor burden is higher in the absence of effector γδ DETCs, one might 
expect greater tumorigenesis in the absence of LC-mediated immune induction. The 
Girardi lab performed the first investigations of chemical carcinogenesis in LC-deficient 
mice. Strikingly, they observed the near elimination of tumors in the DTA cohort 
compared to wild type. Under low dose chemical protocols, wild type mice harbored 
many tumors by week 14 while more than 50% of DTA mice remained tumor free even 
at 16 weeks. The tumor-protective effect in the absence of LCs persisted even at high 
dose chemical protocols [27]. 
Invoking the latest developments in our understanding of the role of dermal and 
epidermal langerin+ DC in adaptive immunity induction, one might predict that the 
absence of LC would substantially decrease LC-mediated immune tolerance and increase 




mice may be more effective at eliminating early transformed cells through heightened 
immune surveillance. However, the Girardi lab also demonstrated that even in the 
absence of αβ T cells – the effector arm of an adaptive immune response against 
transformed cells – LC-deficiency nearly eliminated tumorigenesis [27]. Thus, the tumor 
protective effect afforded by LC-deficiency in the DTA mouse occurred independent of 
an anti-tumor immune response. 
These findings raised a fundamental question about the role of LC in 
carcinogenesis, particularly when induced by PAH. If not an effect on the induction of 
anti-tumor immunity, then what other roles could LC play that might affect 
carcinogenesis? These studies suggested an under-emphasized role of LC early in 
carcinogenesis, likely during tumor initiation. In order to further understand the LC-effect 
on tumorigenesis, we must first take a closer look at the experimental model in which this 
finding occurs. 
 
D.  TWO-STAGE CHEMICAL CARCINOGENESIS 
By employing the tumorigenic influences of PAHs, the chemical carcinogenesis 
experimental model has yielded many insights into the fundamental influences on cancer 
development [28]. Wild type mice on the FVB background are highly susceptible to 
chemical carcinogenesis in a reproducible fashion [29]. As such, these rates can be 
compared to the level of tumor development in a genetically altered mouse with a 
specific phenotype undergoing identical chemical treatment. Varying rates of 




One major limitation to the complete carcinogenesis model is the inability to 
deduce the mechanism of the effect. A variation called two-step chemical carcinogenesis 
circumvents this issue by temporally separating the multi-stage process of carcinogenesis 
into tumor initiation and tumor promotion. Rather than application of a single 
carcinogenic dose to induce tumors, sub-carcinogenic doses of PAHs can be used for 
tumor initiation followed by subsequent treatment with a pro-inflammatory agent for 
tumor promotion. Thus, experiments may be designed to measure effects on initiation 
only, promotion only, or both [30-32]. 
7,12-dimethylbenz[a]anthracene (DMBA) is a very commonly used and well 
described tumor initiating agent. As a result of treatment with DMBA, critical genes in 
epidermal keratinocyte oncogenes acquire mutations, and such cells are considered 
“transformed”. They will not go on to form tumors without a stimulus for clonal 
expansion, which will be provided by the tumor promoting agent. Tumor initiation has 
several prerequisites:  DMBA must diffuse through the stratum corneum, enter into 
keratinocyte stem cells that are thought to be the primary tumor cell, be bioactivated to 
the downstream intermediate called DMBA-3,4-dihydrodiol-1,2-epoxide (DMBADE) 
which is ultimately mutagenic [33], and interact with critical regions of DNA. The Hras 
oncogene appears to be DMBA’s primary target gene and results in an activating 
mutation that can be detected as early as 3-4 weeks after DMBA [34] exposure as well as 
in the majority of papillomas. After bioactivtation, DMBA intermediates induce a 
signature A  T transversion mutation in codon 61 [35, 36]. Assays have been 
developed to quantify initiation by measuring the level of DNA-DMBA adducts, DNA 




The molecular effects of tumor promoting agents such as TPA are more 
pleiotropic. In general, treatment leads to sustained epidermal hyperplasia as evidenced 
by increased number of nucleated cell layers and increased thickness, accompanied by an 
enhanced cell turnover rate [37]. Importantly, initiated cells – that is, those that have 
acquired the critical mutations – are thought to have a survival and proliferative 
advantage that results in the selective expansion of the transformed clone while non-
initiated cells undergo a normal keratinocyte life cycle of division, differentiation, and 
death [28].  
 
E.  DMBA METABOLISM 
As mentioned previously, DMBA is a parent compound that must be metabolized 
to the ultimate carcinogen DMBADE in order to induce the critical Hras mutations. 
While DMBA at high concentrations can be toxic to cells, it is not mutagenic without 
metabolic activation by inducible enzymes including cytochrome p450 (Cyp) family 
members and microsomal epoxide hydroxylase (mEH). Upon entering a cell, DMBA and 
other PAHs are high-affinity ligands for the cytosolic aryl hydrocarbon receptor (AhR), a 
ligand-activated transcription factor that can enter the nucleus and activate the expression 
of xenobiotic response elements (XRE). These include enzymes important for DMBA 
metabolism such as Cyp1a1, Cyp1b1, mEH, and aryl hydrocarbon receptor repressor 
(AhRR).  
Diagram 1 shows the pathway of DMBA metabolism to DMBADE and the 
important enzymes. The XRE enzymes are responsible for either unleashing the toxicity 




metabolizing to other inert intermediates [38]. Accordingly, the collective efforts of 
several investigations demonstrate that mutagenicity and toxicity require a three-step 
reaction to generate DMBADE [38-41]. 
CYP1A1 and CYP1B1 are expressed in varying amounts in different tissues, and 
are very efficient at metabolizing PAH [42]. The development of gene knockout mice in 
which single XRE enzymes are eliminated has facilitated a clearer understanding of the 
DMBA metabolism pathway [43]. Heidel et al investigated the susceptibility of Cyp1B1-
null mice to mutagenesis, in which Cyp1A1 expression remained intact. After systemic 
DMBA treatment, they observed that bone marrow cells did not generate the DNA-
adducts seen in wild type mice. CYP1A1, in fact, metabolizes DMBA at a higher rate 
than CYP1B1. However, given the lack of tumors with sustained Cyp1A1 activity, it 
appears that CYP1A1-mediated DMBA metabolism plays no role in mutagenesis as 
quantified by DNA adducts [38, 44].  
Furthermore, Buters et al demonstrated that Cyp1B1-null mice were almost 
completely protected from the acute bone marrow cytotoxic and leukemic effects of 
DMBA, despite the continued metabolism by hepatic CYP1A1. Thus, collectively, it 
follows that early conversion by CYP1B1 was a requirement for DMBA-induced bone 
marrow toxicity and mutagenisis [44-46]. Kleiner et al recapitulated these findings in 
mouse epidermis. Direct application of DMBA to a Cyp1B1-null mouse resulted in 64% 
reduction in DNA-adduct formation, with similar results seen in the AhR-knockout 
mouse [47]. Cyp1B1-null mice also developed no chemically-induced squamous cell 




After the initial CYP1B1-mediated conversion to DMBA-3,4-epoxide, mEH 
immediately converts it to the penultimate carcinogen DMBA-trans-3,4-diol [48]. Miyata 
et al demonstrated that embryonic fibroblast from mEH-null mice are unable to generate 
DMBA-trans-3,4-diol and are more resistant to DMBA toxicity than fibroblasts from 
wild type mice. By showing that mEH-null mice are almost completely resistant to 
developing DMBA-induced tumors, they demonstrated that mEH is required for DMBA 
carcinogenesis for its role in generation of the proximate carcinogen [49]. The final 
conversion from DMBA-trans-3,4-diol to DMBADE is catalyzed by either CYP1B1 or 
CYP1A1. The bay region of DMBADE is the ultimate carcinogen that interacts with 
DNA [33, 38]. 
 
Diagram 1:  DMBA metabolism pathway.  
 




F.  SITE OF DMBA METABOLISM IN THE EPIDERMIS 
Stem cell keratinocytes of the basal layer adjacent to hair follicles are implicated 
as the cell of origin for skin cancer [50]. These cells express CYP1B1, CYP1A1, mEH, 
and other XRE enzymes, all of which are important to unleash the mutagenicity of 
DMBA. Because downstream metabolites were shown to be extremely reactive, it was 
the widely held view that DMBA’s intermediates could not exist long enough to diffuse 
out of cells [51]. Thus, XRE within keratinocytes were implicated in activating DMBA. 
Kuroki and colleagues supported this hypothesis by demonstrating that primary human 
keratinocytes incubated with the PAH benzo[a]pyrene (BP) could generate HPLC-
identified metabolites of BP. The addition of V79 Chinese hamster cells to this culture 
formed their mutagenesis assay, which correlated ouabain resistance in previously 
sensitive hamster cells as a proxy for tumor initiation. Hamster cells incubated with BP 
and keratinocytes resulted in greater ouabain resistance than hamster cells with just BP 
[52, 53].  
However, there are significant concerns in accepting the hypothesis that 
keratinocytes are the major contributor to DMBA activation. First, the assumption that 
activated intermediates are too unstable to exist for a prolonged period of time has not 
been supported. DMBA-trans-3,4-diol is available in a stable form for experimental use. 
In addition, the concept of intercellular metabolite transfer has been proposed in a 
number of experiments investigating the effects of DMBA on bone marrow cells. 
Supernatant from AhR+ bone marrow stromal cells cultured with DMBA can induce 
apoptosis in bone marrow B cells, while directly incubating B cells with DMBA cannot 




intercellular transfer. Furthermore, the direct application of DMBADE in the absence of 
stromal cells was sufficient to induce an apoptosis profile in B cells, providing evidence 
that the stromal cells metabolize DMBA and transfer a stable intermediate to the B cells 
[55].  
The XRE expression profile of the DMBA-relevant enzymes has been reported in 
a cell type specific fashion of human epidermal cells. After isolating keratinocytes and 
LC from the epidermis of six human donors, the expression of CYP1A1 and CYP1B1 
mRNA relative to GADPH control (expressed as +, ++, or +++) was determined for each 
cell type. Each enzyme was detected in both cell types, however keratinocytes expressed 
greater levels of Cyp1A1 (+++) than Cyp1B1 (++) while the LC expressed greater levels 
of Cyp1B1 (+++) than Cyp1A1 (+, almost undetected) [56]. Taken together, these data 
suggest that CYP1B1 is required for generation of the penultimate mutagen. It also 






II. Statement of Purpose and Hypothesis   
 Our understanding of LC biology has undergone significant changes since 
identification of the cell in the mid-1850s. The discovery that LC-deficient DTA mice are 
resistant to two-stage chemical carcinogenesis offers the possibility for yet another 
advancement to our understanding of LCs and cutaneous biology. Exclusive of immune 
surveillance, a mechanism by which LCs influence chemical carcinogenesis has never 
been described and is precisely the major aim of this investigation. We hypothesize that 
the LC effect will localize early in tumor initiation and that, because of the high 
ratio of Cyp1B1:Cyp1A1 expression, LCs are better equipped to perform the 
requisite DMBA bioactivation necessary for cutaneous chemical carcinogenesis. The 
investigations detailed herein should demonstrate the following:   
1) LC-deficiency abrogates chemical carcinogenesis in the absence of both αβ and 
γδ T cells, thereby excluding enhanced T cell mediated tumor immune 
surveillance to explain tumor resistance. 
2) With the use of a K5Hras transgenic mouse, we observed that the protective effect 
seen in LC-deficiency likely localizes to tumor initiation rather than tumor 
promotion. 
3) To show directly that LC-deficiency influences tumor initiation, we employed a 
novel real time PCR assay to demonstrate that DMBA-exposed LC-deficient mice 
harbor fewer Hras mutations than DMBA-treated wild type mice. 
4) When cultured with DMBA in vitro, the Langerin+ / MHCII+ / Birbeck granule+ 




5) With data suggesting that LCs contribute to tumor initiation by converting DMBA 
to its mutagenic metabolites, we initiated DTA mice with DMBA-trans-3,4-diol 
followed by several weeks of TPA promotion and observed a restoration of 
tumorigenesis. 
6) We examined the XRE mRNA expression profiles present in murine and human 
keratinocytes and LCs after exposure to DMBA in culture, and with the support of 
existing data in the literature, suggest a mechanistic rationale for why LC 
metabolism is required for and keratinocytes metabolism is insufficient for 
carcinogenesis. 
7) LC-deficiency does not confer resistance to UVB-carcinogenesis, however these 






III.  Methods          
A.  ANIMALS AND HOUSING 
All of the in vivo studies were approved by the Yale Animal Care and Use 
Committee. FVB/N mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME). FVB/N Langerhans cell deficient (Lang-DTA) mice were generated with a bacterial 
artificial chromosome-based transgene containing human Langerin which was modified 
to drive expression of diphtheria toxin subunit A from an internal ribosome entry site that 
was inserted in the 3’ untranslated region of the langerin gene (2). TCRδ-/-, TCRβ-/-
TCRδ-/-, and K5Hras transgenic (K5HrasTg) were backcrossed onto the FVB/N 
background for >10 generations and were previously described (15). TCRδ-/- Lang-DTA, 
TCRβ-/-TCRδ-/- Lang- DTA, and K5HrasTg Lang-DTA mice were generated by 
intercrossing the respective mutants. Mice were maintained under specific pathogen-free 
conditions and food and water provided ad libitum. The animal facility is accredited by 
the Association for Assessment of Laboratory Animal Care.  
Renata Filler, Jason Neustadter, and Julie Lewis managed mouse colonies and directed generation of 
the various strains. Badri Modi, Swapna Reddy, and Bernice Kwong, assisted in house keeping issues 
and participated in care of animals.  
 
B.  MICE SORTING AND GENOTYPING 
Approximately 7-12 days after birth, mice were numbered via toe clipping and 
tails were harvested for DNA extraction and subsequent PCR-based genotyping. DNA 
was isolated from tail specimens using the QIAGEN DNeasy® Blood and Tissue kit and 




Blood & Tissue Handbook (07/2006). DNA was amplified with a commercially available 
PCR master mix and 5’, 3’ primers specific for the DTA transgene and TSH transgene. 
After 30 cycles of PCR, DNA was mixed with ethydium bromide dye and run on a 3% 
agarose electrophoresis gel along with a 1kb ladder and a positive control sample (DNA 
from known huLang-DTA). Thus, DNA samples, and their corresponding mice, were 
identified as transgenic+ (tg) or normal littermate control (NLC). Mice were subsequently 
sorted to house roughly equal numbers of Tg and NLC per cage.  
Badri Modi, Renata Filler, Jason Neustadter, Swapna Reddy, and Julia Lewis all participated in 
sorting and genotyping of mice for the various experiments. Badri Modi was involved in data 
analaysis and figure representation for all experiments. 
 
C.  CHEMICAL CARCINOGENESIS: 
 All mice undergoing two-stage chemical carcinogenesis were treated as 
following, according to previously published protocols [57]. At seven weeks of age, the 
hair of a 4x3cm rectangular area on the dorsal surface was clipped with an electric 
shaver, being careful not to cause trauma to the skin. The area was treated with Nair® for 
approximately one minute, which was washed off with water and paper towel. Dorsal 
skin was dried and mice were placed back into cage. One week later, at eight weeks of 
age, each mouse was treated with initiating agent – either DMBA or DMBA-trans-3,4-
diol – reconstituted in acetone. For each experiment, equimolar amounts of initiating 
agent were applied to clipped and naired dorsal skins of NLC and DTA cohorts. At 9 
weeks of age, the mice received twice weekly treatment with equimolar amounts of TPA 
reconstituted in ethanol for the duration of the experiment. The dorsal skin was observed 




clinically scored as papillomas (well demarcated, symmetrical, pedunculated, or dome-
shaped papules without erosion or ulceration) or carcinoma (poorly demarcated, 
assymetrical, sessile or dome-shaped with erosions or ulcerations). At the end of the 
experiment, representative tumors were harvested from each mouse for subsequent 
histologic analysis.  
Badri Modi did the two-stage carcinogenesis experiments with D-3,4-tD as initiating agent, including 
the mouse sorting, genotyping, chemical treatments, tumor charting, and tumor harvesting. Other 
two-stage carcinogenesis experiments were carried out by Jason Neustadter, Renata Filler, and Julia 
Lewis. Badri Modi was involved in data analaysis and figure representation for all experiments. 
 
D.  CELL CULTURE 
 RPMI 1640, DMEM, and media supplements were from Invitrogen, Carlsbad, CA 
unless otherwise noted. CRPMI media was made by supplementing RPMI 1640 with 
10% heat- inactivated FBS, 10mM Hepes, 1% non-essential amino-acids, 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.05 mM -mercaptoethanol, and antibiotics). Mouse 
keratinocyte (mKC) cells were provided by Yale Dermatology Cell Culture Facility. 
CarC cell line (kindly provided by Dr. A. Balmain, UCSF, CA), homozygous for Hras 
codon 61 CAA->CTA mutation, was maintained in DMEM media supplemented with 
10% FBS, 10mM Hepes, 2mM L-glutamine and antibiotics. XS106 and NS46/NS47 cell 
lines were kindly provided by Dr. A. Takashima, U of Toledo, OH. NS46/NS47 cells 
were grown in CRPMI, and the media supernatant was used to supplement media for 
XS106 cells. XS106 cells were grown in “XS106 media” (CRPMI supplemented with 5% 
NS46/NS47 supernatant and 0.5 ng/ml mouse GM-CSF (PeproTech, Rocky Hill, NJ.) 




DMBA. Badri Modi was involved in data analysis and figure representation.  
 
E.  ISOLATION OF GENOMIC DNA 
 Genomic DNA (gDNA) was isolated from cells using DNeasy Blood & Tissue kit 
(Qiagen, Valencia, CA) as per manufacture’s protocol. Mice were sacrificed at a specific 
time point after dorsal skins received chemical treatment. Using blade and scissors, full 
thickness and area of chemically treated murine dorsal skin was excised and the 
subcutaneous fat was scraped off. The gDNA of the remaining dermis and epidermis was 
isolated using the Gentra® Puregene Tissue Kit (Qiagen) as per manufacture’s protocol. 
Each sample underwent further purification via phenol-chloroform-isoamyl extractions 
followed by precipitation with ethanol and 3M sodium acetate. Isolated cell and tissue 
gDNA was analyzed with a NanoDrop (Thermo Scientific, Wilmington, DE) for purity 
and concentration.  
Renata Filler, Jason Neustadter, and Badri Modi isolated genomic DNA for experiments presented in 
this manuscript.  
 
F.  HRAS CLONING AND MUTANT SPECIFIC REAL-TIME PCR 
To quantify the number of DMBA-induced codon-61 Hras CAA->CTA 
mutations, mutant-specific primers 5’-CTAAGCCTGTTGTTTTGCAGGAC and 3’- 
CATGGCACTATACTCTTCTA [34] and a custom TaqMan probe 5’6FAM-
CGGAAACAGGTGGTCAT-MGB3’ were designed as part of a novel real-time PCR 
assay. TaqMan real-time PCR was run on ABI 7500 using SDS 1.4 and SDS 2.0 software 
and TaqMan Gene Expression Master mix (all from ABI Life Technologies Corporation, 




0.078 (ABI Guide to Performing Relative Quantitation of Gene Expression Using Real- 
Time Quantitative PCR). Obtained Ct values were normalized against β-actin and 
expression difference was calculated using the equation RQ=2−ΔΔCt. Serial dilution of 
gDNA from the CarC into aliquots of mKC gDNA provided additional validation of 
TaqMan assay sensitivity. For further verification and validation of the assay, Hras 
240bp PCR product containing codon 61 was cloned from CarC and mKC gDNA and 
singly inserted into pcDNA6.2TM/GW/D-TOPO® expression vector (Invitrogen, 
Carlsbad, CA) and sequenced (W.M. Keck BRL, Yale University). Serial dilutions of a 
known number of plasmids and TaqMan real-time PCR were conducted to generate 
standard curve. Once assay was validated for specificity in Hras-mutant detection, DNA 
from DMBA-treated skins were used in the assay to determine number of Hras mutations 
present in an equimolar amount of DNA.  
Renata Filler, Julia Lewis, Jason Neustadter and Bernice Kwong were involved in the 
development and verification of the assay. Badri Modi used this assay to run other key experiments 
for development of concepts and was involved with data analysis / representation in figure. 
 
G.  GENE EXPRESSION ANALYSIS 
For murine cell line and freshly isolated Langerhans cells:  
 Real- time quantitative RT-PCR (ABI 7500) using SDS 2.0 software was 
performed on RNA isolated using RNeasy Micro kit (Qiagen) from XS106 cells and 
purified Langerhans cells. DNA-free RNA was transcribed using High-Capacity cDNA 
Reverse Transcription kit as per manufacturer’s protocol and used in downstream 
TaqMan assays with TaqMan Gene Expression Master Mix (all from ABI). Obtained Ct 




was calculated using RQ = 2-ΔΔCt equation. 
For human keratinocytes and Langerhans cells: 
 RNA was isolated with RNeasy (Qiagen) kit and was treated with Ambion Turbo 
DNase and then RT Mastermix (ABI) to generate cDNA.Quantitative RTPCR was 
performed on an ABI Prism 7900HT cycler with SYBR Green. Quantitect Primer assays 
from Quiagen were used for quantification of Cyp1a1, Cyp1b1 and β-actin.  
Experiments were carried out by Renata Filler and Julia Lewis. Badri Modi and Julia Lewis 
developed the hypothesis that Cyp1B1 to Cyp1A1 ratio explains why LC-specific metabolism is 
required for DMBA mutagenesis and carcinogenesis. 
 
H.  HPLC AND LC/MS/MS.  
For HPLC XS106 cells were incubated with varying DMBA concentrations of 0, 
4, 16 or 64 µM at 37°C for 24 hr. An additional cell sample containing 16 µM DMBA 
with no cells was incubated under identical conditions. Another sample with XS106 cells 
and 16 µM DMBA was incubated for only 1 hour. HPLC studies were performed by Yale 
W.M. Keck BRL. In brief, to calibrate HPLC equipment and determine standard 
detection times and peak detection heights for DMBA and (+/-)-anti DMBA-3,4-
dihydrodiol-1,2-epoxide (DMBADE), obtained from the NCI Chemical Carcinogen 
Reference Standard Repository, standard concentrations of DMBA and DMBADE at 4, 
8, 16, 32 and 64 µM were prepared in 30% methanol. 50 µl of each was injected onto the 
HPLC system in an identical manner as for the experimental samples. For LC/MS/MS 
detection and quantification XS106 cells were incubated for 24 hr in F10 media (which 
has reduced tryptophan concentration) with 10% dialyzed FBS (both from Sigma), 10mM 




mM β-mercaptoethanol, antibiotics, 5% NS46/NS47 supernatant, and 0.5 ng/ml mouse 
GM-CSF. The following day 32 µM or 64 µM of DMBA was added to the cultures and 
allowed to incubate for additional 24 hr after which media and cells were harvested and 
sent to Lining Cai and Peter Fu (Biotranex, FDA). Following extraction, samples were 
analyzed using LC/MS/MS methods developed by Biotranex to quantify the amount of 
DMBA-trans-3,4-diol.  
Experiments were carried out by Renata Filler, Julia Lewis, and Jason Neustadter. Badri Modi was 
involved with data analysis and figure representation. 
 
I.  CHRONIC UV EXPERIMENT 
Ten huLang.DTA.FVB and ten NLC.FVB mice at 8 weeks of age were shaved 
and sorted for this experiment. Three days later, mice were exposed to UVB from three 
broadband FS20T12-UVB lamps filtered through a Kodacel filter (Eastman Kodak) to 
remove wavelengths below 290nm [58]. Mice were exposed to 500 J/m2 for three days 
during the first week. During the second week, mice were exposed to 750 J/m2 for two 
days and then 1000 J/m2 for three days. Then, mice were exposed to 1250 J/m2 for five 
days per week, for the next 29 weeks.  
Badri Modi carried out all aspects of this experiment, with planning and guidance from others. 
 
Michael Girardi designed and directed most of the planning, troubleshooting, and analysis 







J.  STATISTICS 
Statistical significance was evaluated by the two-tailed, unpaired Student’s t-test. 






IV.  Results          
A.  Resistance to two-stage chemical carcinogenesis is αβ  and γδ  T cell independent 
 The dramatic tumor resistance observed in TCRβ(-/-).huLang-DTA mice 
provided early evidence that the impact of LC-deficiency are independent of adaptive 
immunity. However, because LC can express T cell suppressive cytokines such as IL-10 
[59, 60], we still considered the possibility that the absence of LC led to an augmented T-
cell mediated anti-tumor immune response and, accordingly, abrogation of tumors. γδ T 
cells are intraepithelial lymphocytes, unique from the systemically circulating αβ T cells, 
that have been shown to regulate chemical carcinogenesis [14]. TCRδ−/− developed 
more tumors after DMBA/TPA than their counterparts. To further examine the role of the 
adaptive immune response’s effector T cells in LC-deficiency, chemical carcinogenesis 
was induced in (Figure 1A) Tcrβ−/− Tcrδ−/− Lang-DTA mice using 50 mg DMBA to 
initiate and 6.25 mg TPA/week to promote, as well as in (Figure 1B) Tcrδ−/− Lang-DTA 
mice using100 mg DMBA to initiate and 25 mg TPA/week to promote. Even in the 
absence αβ and γδ T cells, LC-deficiency conferred a dramatic resistance to two-stage 





Figure 1:  
 
 
B.  LC-deficiency does not prevent tumorigenesis in K5Hras mice 
The K5Hras transgenic mouse expresses a constitutively activated Hras gene 
within basal keratinocytes. When expressed on the FVB background, many of these mice 




cell carcinoma [61], in the absence of any chemical exposure. Since these mice are 
effectively already initiated, we investigated if the absence of LC would eliminate 
tumors. Therefore, we crossed huLang-DTA.FVB x K5Hras.FVB and compared rates of 
tumorigenesis in the double transgenic mice with the K5Hras.FVB mice. Both cohorts 
developed tumors at a similar rate with a non-significant difference in percentage of 
tumor-free mice and average tumor area per animal (Figure 2). The huLang-DTA 
transgene had no significant effect on rate of tumorigenesis in the K5Hras.FVB mouse. 
Thus, the tumor-protective effect seen in LC-deficiency could not overcome the 
tumorigenic fate of an “initiated” background, suggesting that LC influence acquisition of 









C. DMBA induces fewer Hras mutations in LC-deficient mice than in wild type mice 
At this point, we strongly believed that the LC-effect occurred early in 
carcinogenesis, yet we lacked direct evidence demonstrating this. Thus, our lab devised a 
novel TaqMan real time polymerase chain reaction (RT-PCR) based mutagenesis assay – 
modified from a previous report [34] – that would enable the relative quantification of 
Hras mutations in DMBA-treated DTA and WT mice. The assay utilized TaqMan probes 
and primers that would selectively amplify and quantify only the alleles harboring the 
signature DMBA induced codon 61 Hras mutation.  
 We first verified the validity of the mutagenesis assay using plasmids and DNA 
from the CarC cell line, which harbors two mutant Hras alleles. Hras 240bp PCR product 
containing codon-61 was cloned from CarC (mutant Hras) and mKC (WT Hras) cell 
gDNA and inserted into pcDNA6.2TM/GW/D-TOPO® expression vector and sequenced 
for verification (Figure 3A). Knowledge of the plasmid sequence enabled derivation of 
plasmid mass (1plasmid = 5.486E-18 grams, or 18227 plasmids in 0.1pg). Thus, by 
running RT-PCR on serial dilutions of known number of mutant plasmids mixed, we 
were able to determine the lower limit of mutant allele detection. The assay could detect 
as few as 8 mutant plasmids (Figure 3B). The sensitivity of the assay was not affected by 
the presence of wild type Hras sequences. Thus, the novel mutagenesis assay was 
effective at detecting and quantifying the relative number of Hras mutants present in a 
given sample. 
 With the assay validated, the focus shifted back to examining DTA and WT mice 
for relative amounts of mutant Hras present in their DMBA-treated epidermis. This 




cohorts of mice were treated with DMBA, followed by 2 weeks, 4 weeks, or 6 weeks of 
TPA. Previous attempts at identifying Hras mutant alleles in non-promoted skin were 
unsuccessful (data not shown); therefore, minimal and equal amounts of TPA were used. 
DNA was harvested from the DMBA-treated regions of each group and purified for 
analysis in the mutagenesis assay. For each TPA cohort, significantly fewer Hras 
mutations were detected in DTA mice compared to WT mice, and this result was 
unaffected by the absence of T cells (Figure 3C). Thus, in a T-cell independent fashion, 










D.  XS106 cells cultured with DMBA generate DMBA-trans-3,4-diol 
 Considering the events that must take place prior to acquisition of Hras mutations 
during chemical carcinogenesis, the major events include DMBA diffusion through the 
stratum corneum, metabolic activation to mutagenic intermediates, and interaction with 
DNA. Previous reports examining the DTA mouse epidermis revealed no structural 
differences compared to a wild type mouse except the absence of LC [23]. Pre-treatment 
epidermal and stratum corneum combined thickness is largely equivalent between DTA 
and NLC mice [27]. Thus, we focused our efforts at assessing the possible role LC may 
play in the bioactivation of DMBA.  
In order to investigate the capacity for LC to generate mutagenic intermediates, 
XS106 cells, which are stable cell lines derived from murine LC [62], were cultured with 
DMBA for 24 hours. High-performance liquid chromatography (HPLC) analysis of cell 
lysates revealed internalization of DMBA, while analysis of supernatant identified 
DMBA metabolites (Figure 4, A and B). The concentration of XS106-internalized 
DMBA increased with increasing initial DMBA concentrations (Figure 4C). Notably, 
there was a very rapid accumulation of DMBA metabolites in the medium of XS106 
cells, which also increased over time and with the concentration of DMBA (Figure 4, D 
and E). These data are consistent with the cells’ uptake and metabolism of DMBA and 
the rapid release of metabolites. Liquid chromatography / tandem mass spectrometry 
(LC/MS/MS) identified the mutagenic metabolite DMBA-trans-3,4-diol in the cultures, 
at mean concentrations of 29.2nM and 42.4nM when initial DMBA concentrations were 
32µM and 64µM, respectively (Figure 4F). Thus, the LC-derived XS106 cells are able to 







E.  Initiation with DMBA-trans-3,4-diol restores tumorigenesis in the DTA mouse 
After observing that in vitro LC can generate mutagenic intermediates, we aimed 
to investigate directly whether the LC-requirement for tumorigenesis reflected the cells’ 
release of DMBA metabolites. We initiated WT and DTA mice with 100µg DMBA-
trans-3,4-diol followed by standard promotion with TPA. Unlike the resistance observed 
after DMBA initiation, DTA mice were susceptible to tumorigenesis at a comparable 
level to WT when initiated with the DMBA-trans-3,4-diol (Figure 5). The restoration of 
tumors with metabolite initiation demonstrated that the LC-requirement for chemical 
carcinogenesis can be bypassed by artificially providing metabolism. Not only do these 
findings demonstrate the importance of LC-specific metabolism for carcinogenesis, but 
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F.  Keratinocyte XRE expression favors Cyp1A1, while LCs expression favors 
Cyp1B1 
 In considering the ability of keratinocytes and LCs to metabolize DMBA, we 
investigated the XRE expression profile of primary murine keratinocyte and primary 
murine LCs before and 24-hours after DMBA exposure. After creating epidermal cell 
suspensions of DMBA-unexposed and -exposed skin, keratinocytes were sorted based on 




cell type revealed that keratinocytes and LCs have a different expression profile in 
response to DMBA. LCs did not express Cyp1a1 either before or after DMBA, while 
there was a two-fold increase in AhR, Cyp1b1, and EPXH1 after DMBA. Overall enzyme 
expression levels were greater in keratinocytes than LCs, however keratinocytes heavily 
favored Cyp1a1 expression over Cyp1b1 (Figure 6, A and B). Thus, the Cyp1b1 to 
Cyp1a1 ratio was 0.108 in keratinocytes, whereas it approached infinity LCs.  
Given that these data indicate the major contribution of murine LCs to cutaneous 
chemical carcinogenesis is mediated by non-immunological properties, it was appropriate 
to determine whether human LCs might display equivalent properties with the potential 
to facilitate disease. We therefore examined the response to DMBA of primary human 
LCs from several donors, and their consequent effects on primary keratinocytes. The data 
are consistent with the murine data sets and previous reports in the literature [56]. 
Following DMBA treatment, human LCs express substantially more Cyp1b1 than 
Cyp1a1 (of which most donors’ cells express negligible levels), whereas human 
keratinocytes express an excess of Cyp1a1 (Figure 6C). For most donors, Cyp1b1 
expression by DMBA-treated LC was ~20-fold higher than that in keratinocytes, whereas 











G.  LC-deficient mice develop UVB-induced tumors at the same rate as wild type 
mice 
 The data presented thus far implied that the LC contribution to carcinogenesis is 
unique to the chemical carcinogenesis model. We questioned if the profound resistance 
seen in chemically treated LC-deficient mice would be observed in UVB-carcinogenesis 
protocols. In order to investigate the impact of LC-deficiency on UVB-induced tumors, 




thirty weeks. Four out of ten NLC mice harbored tumors by week 24 of treatment, 
whereas all LC-deficient mice remained tumor-free (Figure 7A). NLC mice harbored 
significantly more tumors and a significantly larger tumor area early during tumor 
development. On week 24, average tumor number per mouse was 0.5±0.2 for NLC and 0 
for DTA mice (p-value = 0.019). Average tumor area was 5.6mm2±2.8 for NLC and 0 for 
DTA mice (p-value = 0.031). With continued UVB treatment, however, DTA mice began 
developing tumors. At week 29 (Figure 7B), there was no longer a statistically 
significant difference between the two cohorts. Average tumor number per mouse was 
2.5±0.69 for NLC and 1.6±0.27 for DTA mice (p-value = non-significant). Thus, LC-
deficiency did not protect against UVB-induced tumors, although it did delay onset of 
tumors by a short period of time. 
 
Figure 7A:  Tumor number and tumor area per mouse at 24 weeks of UVB treatment. 
 











V.  Discussion         
 The immunological influences on cancer biology elucidated to date traverse a 
wide range of effects. Clinical evidence definitively demonstrates that the immune 
system is intimately related to cancer in both enhancing and inhibiting capacities. As the 
major immune constituents present in mouse epidermis, γδ DETCs and LCs represent the 
interface of the immune system and cutaneous epithelial tumors. Furthermore, the skin 
epithelial surface faces with an ever-growing level of mutagenic PAHs found in the 
environment. While γδ DETCs provide an anti-tumor effect on chemical carcinogenesis 
in which their absence leads to higher rates of tumors [14], LCs contribute an effect so 
critical to tumorigenesis that their absence results in nearly complete elimination of 
DMBA/TPA-induced cutaneous papilloma and squamous cell carcinoma [27]. 
 With dendritic processes extending in all directions, LCs are strategically 
positioned to interact with carcinogenic compounds in the environment and the 
keratinocyte stem cells of the epidermis [1]. Until the development of LC-deficient 
mouse models, our understanding of LC biology has primarily centered on its role in 
antigen presentation and regulating an adaptive immune response [22]. Here, we shift the 
LC-paradigm further and describe a novel pathophysiologic role for LC in the 
development of cancer that is independent of αβ and γδ T cell-mediated immunity 
(Figure 1). LC-deficient epidermis harbored fewer Hras1 mutations than wild type skin 
(Figure 3); in vitro LC generated the proximate carcinogen DMBADE (Figure 4); and 
direct initiation with DMBA-trans-3,4-diol restored tumorigenesis on DTA mice (Figure 
5). LC-deficiency did not eliminate UVB-carcinogenesis, although tumors developed 




facilitate carcinogenesis in neighboring keratinocytes through inherent scavenging 
properties and enzymatic processing that generates the critical mutagenic metabolites.  
 
A.  RATIO HYPOTHESIS 
Our findings further suggest that keratinocytes, by themselves, are inadequate in 
unleashing DMBA’s mutagenic potential, and investigations into the cell-specific 
expression of XRE enzymes reveal a possible explanation. In both mice and humans, we 
observed a preferential expression of Cyp1B1 > Cyp1A1 in LC and Cyp1A1 > Cyp1B1 in 
keratinocyte (Figure 6).  Invoking the conclusions of Kleiner and Buters that Cyp1B1 is 
required for generation of mutagenic intermediates [47] and that Cyp1A1 has a faster 
pharmacokinetics profile [46], it follows that the low Cyp1B1 to Cyp1A1 ratio in 
keratinocytes would skew metabolism towards generation of non-mutagenic metabolites 
mediated predominantly by Cyp1A1. The high ratio of Cyp1B1 to Cyp1A1 in LCs enables 
these cells to preferentially generate the proximate carcinogen DMBA-trans-3,4-diol. 
Others have revealed the potential for non-epithelial stromal cells to activate PAHs [63, 
64]. The observation of decreased Hras1 mutations in LC-deficient mice, in which 
keratinocytes are normal and abundant, offers in vivo evidence to reject that keratinocyte 
XRE enzymes are the metabolic machinery catalyzing DMBA activation. The lack of 
tumors in LC-deficient mice further recapitulates this notion. 
The relevance of Cyp1B1 to cancer biology has been investigated from many 
aspects. For instance, it is expressed at higher levels in tumor samples compared to 
normal counterparts [65]. Individuals who smoke cigarettes, which contains the PAH BP, 




mediated metabolism contributes to PAH-carcinogenesis [44, 46], data derived from 
colonic adenocarcinoma models suggest that Cyp1B1 is protective against endogenous 
carcinogenic substrates [67]. Thus, these data offer a teleological explanation for why LC 
may have evolved a “cancer-promoting” Cyp1B1:Cyp1A1 ratio. The increased 
interactions between PAH and the epidermis in industrialized societies perhaps facilitate 
the hijacking of a protective effect that LC Cyp1B1 evolved to perform. Future 
investigations should pursue the development of an LC-specific Cyp1B1 knockout mice. 
The use of this animal model would not only confirm the findings presented herein if 
resistance to DMBA carcinogenesis is observed, but it would also facilitate investigations 
into the positive roles of LC Cyp1B1. 
 
B.  COOPERATIVE CARCINOGENESIS  
LCs are located adjacent to both inter- and intra- follicular basal keratinocytes 
[68], and hair follicle bulge cells have been strongly implicated as targets of cutaneously 
applied chemical mutagens [69]. Given LC and keratinocyte stem cell proximity, our data 
imply a cooperative carcinogenesis scenario in which keratinocyte mutagenesis requires 
neighboring LC-mediated DMBA activation (Diagram 2). In this proposed model, LC 
must first internalize DMBA (1), perhaps via simple diffusion or through a more 
sophisticated process such as endocytosis.  Next, LC-specific Cyp1B1 and EPXH1 
generate DMBA-trans-3,4-diol (1), which then traverse out of LC and into adjacent 
keratinocytes (2) for further metabolism to DMBADE. Within keratinocytes, the ultimate 
carcinogen displays a well-described, strong affinity for the Hras gene at codon 61 (3) 




DMBA’s effects, which corroborate that non-epithelial “stromal” cells are critical for 
DMBA-activation [54, 55].  
 




C.  IMPLICATIONS FOR OTHER CUTANEOUS AND NON-CUTANEOUS TUMORS  
LCs neighbor other epidermal cellular constituents including melanocytes. Their 
proximity, coupled with the increasing body of evidence that activation of the ras family 
of oncogenes is necessary for human melanoma development [70], implicates LC-
mediated cooperative carcinogenesis and PAH in melanoma biology. Although patients 
with human familial melanoma syndromes – alterations in Cdkn2a and/or Cdk4 – exhibit 
a higher incidence of clinical melanomas, mice genetically engineered to mimic these 
syndromes result in a very low incidence of spontaneous melanoma [71]. In these 
animals, the high melanoma incidence is restored by inducible expression of Hras [72]. 




existing melanomas [72]. Indeed, in mice with low melanoma incidence despite 
expressing alterations in Cdk4, DMBA treatment also restored heightened melanoma 
development [73, 74]. The melanocytes of human Spitz nevi have been shown to possess 
mutations and copy number amplifications of the Hras gene [75]. Thus, these findings 
warrant further investigation into the contribution of LC-mediated metabolism of PAH to 
pigment cell ras activation. 
Furthermore, our findings hold implications for carcinoma of non-cutaneous 
epithelial tissues, such as the GI and respiratory tracts. Arguably, these epithelial surfaces 
are exposed to some of the highest levels of PAHs secondary to their presence in certain 
foods and cigarette smoke. The presence of intraepithelial immune cells in these non-
cutaneous epithelial surfaces raises the possibility that tissue specific immune cells might 
have similar non-immunologic contributions to PAH-mutagenesis. Our findings justify 
future investigations to evaluate XRE expression profiles of other tissue-specific 
dendritic cells. 
 
Our findings offer a novel target for the reduction in PAH-induced ras mutations 
in non-melanoma skin cancers, and possibly for melanoma and epithelial transformations 
throughout the body. With therapies targeting LC-specific Cyp1B1 metabolism, perhaps 
the mutagenic effects of PAH found in the environmental, cigarette smoke, and certain 
foods may be mitigated. Nevertheless, these findings demonstrate that tissue-associated 
DC can enhance chemical carcinogenesis via PAH metabolism, highlighting the complex 





VI.  Figure Legends        
Diagram 1.  DMBA metabolism pathway. The metabolism of DMBA to the principle 
proximate carcinogen DMBA-trans-3,4-diol and the ultimate mutagen DMBADE is 
depicted as adapted from Miyata, et al. [49]  
 
Figure 1.  Resistance to two-stage chemical carcinogenesis is  αβ  and γδT cell–
independent. Chemical carcinogenesis was induced in (A) Tcrβ−/− Tcrδ−/− Lang-DTA 
mice using 50 mg DMBA to initiate and 6.25 mg TPA/week to promote, as well as in (B) 
Tcrδ−/− Lang-DTA mice using 100 mg DMBA to initiate and 25 mg TPA/week to 
promote. The mean numbers of tumors per mouse (left) and individual tumor area (right) 
14 weeks post-initiation are shown. ***P < 0.0001 (Student’s t test); n = 8 to 12 mice per 
group. NS, not significant. (C) Representative images from (B). 
 
Figure 2. LC-deficiency does not prevent tumorigenesis in K5Hras mice. K5HrasTg-
Lang-DTA and K5HrasTg littermates were monitored for spontaneous tumor 
development. LC-deficient and LC-intact mice had equivalent tumor incidence and 
individual tumor area. 
 
Figure 3.  DMBA induces fewer Hras mutations in LC-deficient mice than in wild 
type mice.  (A) Hras1 240bp PCR product containing codon-61 was cloned from CarC 
(mutant) and mKC (WT) cell gDNA and inserted into pcDNA6.2TM/GW/D-TOPO® 
expression vector and sequenced for verification. (B) Real time PCR using mutant-




order to determine the lower limit of mutant copy detection. As few as 8 mutant plasmids 
were detected in this system, while normal plasmids were not detectable with mutant 
primers. (C) DMBA was applied to the dorsal skin of both NLC and DTA mice, followed 
by application of 2, 4, or 6 weeks of TPA (twice/week). DNA was harvested for mutation 
quantification. DNA from LC-intact skin harbored more Hras-61 mutants than DNA 
from LC-deficient skin *P < 0.05 (Student’s t test), in a TPA-dose dependent manner. 
LC-deficiency protected against acquiring Hras-61 mutation even in the absence of αβ 
and γδ T cells *P < 0.05 (Student’s t test). 
 
Figure 4. XS106 cells cultured with DMBA generate DMBA-trans-3,4-diol. XS106 
cells were cultured with 64 mM DMBA for 24 hours, the supernatant was then collected, 
and cells were pelleted to prepare a lysate. (A and C) HPLC analysis of the lysate. (B, D, 
and E) HPLC analysis of the supernatant. (F) LC/MS/MS analysis of XS106 cells in the 
presence or absence of DMBA. 
 
Figure 5. Initiation with DMBA-trans-3,4-diol restores tumorigenesis in the DTA 
mouse. (A) Tumor induction was measured after treatment with DMBA (12.5 mg) or 
DMBA-trans-3,4-diol (100 mg). 25 mg/week TPA promotion was used in both groups, 
and initiator doses were chosen on the basis of predicted diol instability, reduced 
cutaneous penetrance, and preliminary studies. Each dot represents an individual mouse. 
***P < 0.0001 (Student’s t test).  (B and C) Representative images from (A). 
 




Primary murine LCs (A) and keratinocytes (B) were cultured with and without DMBA 
for 24 hours, after which Cyp1B1 to Cyp1A1 expression was quantified relative to β-actin 
by qPCR. (C) Human keratinocytes or LCs were cultured in the presence (right) or 
absence (left) of 64 mM DMBA for 24 hours, then Cyp1a1 (1A1) and Cyp1b1 (1B1) 
expression was quantified relative to β-actin by qPCR. 
 
Figure 7. LC-deficient mice develop UVB-induced tumors at the same level as LC-
intact mice.  Tumor induction was measured as tumor number and tumor area at (A) 24 
weeks and again at (B) 29 weeks post-initiation of 5-time weekly UVB treatment. 
 
Diagram 2.  Cooperative chemical carcinogenesis scenario.  Illustration of proposed 
mechanism by which LCs contribute to chemical carcinogenesis. (1) LCs internalize 
DMBA, where LC-specific CYP1B1 and mEH convert DMBA to DMBA-trans-3,4-diol. 
(2) This metabolite moves out of LCs and into keratinocytes where it undergoes further 
metabolism to DMBADE. (3) The ultimate mutagen exerts effects on keratinocyte Hras 
gene. 
 
Image 1.  LC internalize DMBA.  Confocal image depicting MHCII+ (green) cells 




VII.  References         
1. Lewis, J., et al., The contribution of Langerhans cells to cutaneous malignancy. 
Trends Immunol, 2010. 31(12): p. 460-6. 
2. Marchiando, A.M., W.V. Graham, and J.R. Turner, Epithelial barriers in 
homeostasis and disease. Annu Rev Pathol, 2010. 5: p. 119-44. 
3. Khavari, P.A., Modelling cancer in human skin tissue. Nat Rev Cancer, 2006. 
6(4): p. 270-80. 
4. Alam, M. and D. Ratner, Cutaneous squamous-cell carcinoma. N Engl J Med, 
2001. 344(13): p. 975-83. 
5. Miller, D.L. and M.A. Weinstock, Nonmelanoma skin cancer in the United 
States: incidence. J Am Acad Dermatol, 1994. 30(5 Pt 1): p. 774-8. 
6. Mastrangelo, G., E. Fadda, and V. Marzia, Polycyclic aromatic hydrocarbons and 
cancer in man. Environ Health Perspect, 1996. 104(11): p. 1166-70. 
7. Wang, Y. and et al., Combined subcarcinogenic benzo[a]pyrene and UVA 
synergistically caused high tumor incidence and mutations in H- ras gene, but not 
p53, in SKH-1 hairless mouse skin. 2005. 116: p. 193-199. 
8. Nair, S., et al., UVR exposure sensitizes keratinocytes to DNA adduct formation. 
Cancer Prev Res (Phila), 2009. 2(10): p. 895-902. 
9. Euvrard, S., J. Kanitakis, and A. Claudy, Skin cancers after organ 
transplantation. N Engl J Med, 2003. 348(17): p. 1681-91. 
10. Oehler-J‰nne, C., et al., HIV-specific differences in outcome of squamous cell 
carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients 
receiving highly active antiretroviral therapy. J Clin Oncol, 2008. 26(15): p. 
2550-7. 
11. Kim, R., M. Emi, and K. Tanabe, Cancer immunoediting from immune 
surveillance to immune escape. Immunology, 2007. 121(1): p. 1-14. 
12. Girardi, M., et al., The distinct contributions of murine T cell receptor 
(TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically 
induced skin cancer. J Exp Med, 2003. 198(5): p. 747-55. 
13. Schwartz, O., Langerhans cells lap up HIV-1. Nat Med, 2007. 13(3): p. 245-6. 
14. Girardi, M., Regulation of cutaneous malignancy by gamma-delta T cells. 
Science, 2001. 294(5542): p. 605-609. 
15. Jolles, S., Paul Langerhans. J Clin Pathol, 2002. 55(4): p. 243. 
16. Romani, N., B.E. Clausen, and P. Stoitzner, Langerhans cells and more: langerin-
expressing dendritic cell subsets in the skin. Immunol Rev, 2010. 234(1): p. 120-
41. 
17. Stingl, G., et al., Epidermal Langerhans cells bear Fc and C3 receptors. Nature, 
1977. 268(5617): p. 245-6. 
18. Rowden, G., M.G. Lewis, and A.K. Sullivan, Ia antigen expression on human 
epidermal Langerhans cells. Nature, 1977. 268(5617): p. 247-8. 
19. Klareskog, L., et al., Epidermal Langerhans cells express Ia antigens. Nature, 
1977. 268(5617): p. 248-50. 
20. Heath, W.R. and F.R. Carbone, Dendritic cell subsets in primary and secondary T 




21. Merad, M., et al., Langerhans cells renew in the skin throughout life under 
steady-state conditions. Nat Immunol, 2002. 3(12): p. 1135-41. 
22. Romani, N., P.M. Brunner, and G. Stingl, Changing Views of the Role of 
Langerhans Cells. J Invest Dermatol, 2012. 
23. Kaplan, D.H., et al., Epidermal langerhans cell-deficient mice develop enhanced 
contact hypersensitivity. Immunity, 2005. 23(6): p. 611-20. 
24. Dudziak, D., et al., Differential antigen processing by dendritic cell subsets in 
vivo. Science, 2007. 315(5808): p. 107-11. 
25. Bursch, L.S., et al., Identification of a novel population of Langerin+ dendritic 
cells. J Exp Med, 2007. 204(13): p. 3147-56. 
26. Kaplan, D.H., In vivo function of Langerhans cells and dermal dendritic cells. 
Trends Immunol, 2010. 31(12): p. 446-51. 
27. Strid, J., et al., Acute upregulation of an NKG2D ligand promotes rapid 
reorganization of a local immune compartment with pleiotropic effects on 
carcinogenesis. Nat Immunol, 2008. 9(2): p. 146-54. 
28. Abel, E.L., et al., Multi-stage chemical carcinogenesis in mouse skin: 
fundamentals and applications. Nat Protoc, 2009. 4(9): p. 1350-62. 
29. Hennings, H., et al., FVB/N mice: an inbred strain sensitive to the chemical 
induction of squamous cell carcinomas in the skin. Carcinogenesis, 1993. 14(11): 
p. 2353-8. 
30. DiGiovanni, J., Multistage carcinogenesis in mouse skin. Pharmacol Ther, 1992. 
54(1): p. 63-128. 
31. Yuspa, S.H., The pathogenesis of squamous cell cancer: lessons learned from 
studies of skin carcinogenesis. J Dermatol Sci, 1998. 17(1): p. 1-7. 
32. Kemp, C.J., Multistep skin cancer in mice as a model to study the evolution of 
cancer cells. Semin Cancer Biol, 2005. 15(6): p. 460-73. 
33. Wislocki, P.G., et al., Carcinogenicity and mutagenicity of the 3,4-dihydrodiols 
and other metabolites of 7,12-dimethylbenz(a)anthracene and its hydroxymethyl 
derivatives. Cancer Res, 1980. 40(10): p. 3661-4. 
34. Nelson, M.A., et al., Detection of mutant Ha-ras genes in chemically initiated 
mouse skin epidermis before the development of benign tumors. Proc Natl Acad 
Sci U S A, 1992. 89(14): p. 6398-402. 
35. Balmain, A., et al., Activation of the mouse cellular Harvey-ras gene in 
chemically induced benign skin papillomas. Nature, 1984. 307(5952): p. 658-60. 
36. Ise, K., et al., Targeted deletion of the H-ras gene decreases tumor formation in 
mouse skin carcinogenesis. Oncogene, 2000. 19(26): p. 2951-6. 
37. Karen, J., et al., 12-O-tetradecanoylphorbol-13-acetate induces clonal expansion 
of potentially malignant keratinocytes in a tissue model of early neoplastic 
progression. Cancer Res, 1999. 59(2): p. 474-81. 
38. Gonzalez, F.J. and S. Kimura, Understanding the role of xenobiotic-metabolism 
in chemical carcinogenesis using gene knockout mice. Mutat Res, 2001. 477(1-2): 
p. 79-87. 
39. Slaga, T.J., et al., Potent tumor-initiating activity of the 3,4-dihydrodiol of 7,12-





40. Cavalieri, E.L. and E.G. Rogan, The approach to understanding aromatic 
hydrocarbon carcinogenesis. The central role of radical cations in metabolic 
activation. Pharmacol Ther, 1992. 55(2): p. 183-99. 
41. Kleiner, H.E., et al., Role of cytochrome P450 1a1 and 1b1 in the metabolic 
activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally 
occurring furanocoumarins on skin tumor initiation. Chem Res Toxicol, 2002. 
15(2): p. 226-35. 
42. Nebert, D.W. and D.W. Russell, Clinical importance of the cytochromes P450. 
Lancet, 2002. 360(9340): p. 1155-62. 
43. Gonzalez, F.J., The use of gene knockout mice to unravel the mechanisms of 
toxicity and chemical carcinogenesis. Toxicol Lett, 2001. 120(1-3): p. 199-208. 
44. Heidel, S.M., et al., Cytochrome P4501B1 mediates induction of bone marrow 
cytotoxicity and preleukemia cells in mice treated with 7,12-
dimethylbenz[a]anthracene. Cancer Res, 2000. 60(13): p. 3454-60. 
45. Heidel, S.M., C.J. Czuprynski, and C.R. Jefcoate, Bone marrow stromal cells 
constitutively express high levels of cytochrome P4501B1 that metabolize 7,12-
dimethylbenz[a]anthracene. Mol Pharmacol, 1998. 54(6): p. 1000-6. 
46. Buters, J.T., et al., Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-
dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A, 
1999. 96(5): p. 1977-82. 
47. Kleiner, H.E., et al., Role of cytochrome p4501 family members in the metabolic 
activation of polycyclic aromatic hydrocarbons in mouse epidermis. Chem Res 
Toxicol, 2004. 17(12): p. 1667-74. 
48. Gao, J., et al., Cytochrome P450 1B1 is required for 7,12-dimethylbenz(a)-
anthracene (DMBA) induced spleen cell immunotoxicity. Toxicol Sci, 2005. 
86(1): p. 68-74. 
49. Miyata, M., et al., Targeted disruption of the microsomal epoxide hydrolase gene. 
Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-
dimethylbenz[a]anthracene. J Biol Chem, 1999. 274(34): p. 23963-8. 
50. Cotsarelis, G., T.T. Sun, and R.M. Lavker, Label-retaining cells reside in the 
bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, 
and skin carcinogenesis. Cell, 1990. 61(7): p. 1329-37. 
51. Guengerich, F.P., Metabolism of chemical carcinogens. Carcinogenesis, 2000. 
21(3): p. 345-51. 
52. Kuroki, T., et al., Metabolism of benzo(a)pyrene in epidermal keratinocytes and 
dermal fibroblasts of humans and mice with reference to variation among species, 
individuals, and cell types. Cancer Res, 1982. 42(5): p. 1859-65. 
53. Kuroki, T., N. Nemoto, and Y. Kitano, Metabolism of benzo[a]pyrene in human 
epidermal keratinocytes in culture. Carcinogenesis, 1980. 1(7): p. 559-65. 
54. Allan, L.L., et al., Bone marrow stromal-B cell interactions in polycyclic 
aromatic hydrocarbon-induced pro/pre-B cell apoptosis. Toxicol Sci, 2003. 
76(2): p. 357-65. 
55. Teague, J.E., et al., Proximal events in 7,12-dimethylbenz[a]anthracene-induced, 
stromal cell-dependent bone marrow B cell apoptosis: stromal cell-B cell 




56. Saeki, M., et al., mRNA expression of multiple cytochrome p450 isozymes in four 
types of cultured skin cells. Int Arch Allergy Immunol, 2002. 127(4): p. 333-6. 
57. Roberts, S.J., et al., Characterizing tumor-promoting T cells in chemically 
induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A, 2007. 104(16): p. 
6770-5. 
58. Zhang, W., et al., Escaping the stem cell compartment: sustained UVB exposure 
allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating 
units without incurring additional mutations. Proc Natl Acad Sci U S A, 2001. 
98(24): p. 13948-53. 
59. de Saint-Vis, B., et al., The cytokine profile expressed by human dendritic cells is 
dependent on cell subtype and mode of activation. J Immunol, 1998. 160(4): p. 
1666-76. 
60. O'Garra, A. and K.M. Murphy, From IL-10 to IL-12: how pathogens and their 
products stimulate APCs to induce T(H)1 development. Nat Immunol, 2009. 
10(9): p. 929-32. 
61. Wakabayashi, Y., et al., Promotion of Hras-induced squamous carcinomas by a 
polymorphic variant of the Patched gene in FVB mice. Nature, 2007. 445(7129): 
p. 761-5. 
62. Xu, S., et al., Successive generation of antigen-presenting, dendritic cell lines 
from murine epidermis. J Immunol, 1995. 154(6): p. 2697-705. 
63. Gould, M.N., Chemical carcinogen activation in the rat mammary gland: intra-
organ cell specificity. Carcinogenesis, 1982. 3(6): p. 667-9. 
64. Gould, M.N., L.E. Cathers, and C.J. Moore, Human breast cell-mediated 
mutagenesis of mammalian cells by polycyclic aromatic hydrocarbons. Cancer 
Res, 1982. 42(11): p. 4619-24. 
65. Murray, G.I., et al., Tumor-specific expression of cytochrome P450 CYP1B1. 
Cancer Res, 1997. 57(14): p. 3026-31. 
66. Chi, A.C., et al., Differential induction of CYP1A1 and CYP1B1 by 
benzo[a]pyrene in oral squamous cell carcinoma cell lines and by tobacco 
smoking in oral mucosa. Oral Oncol, 2009. 45(11): p. 980-5. 
67. Halberg, R.B., et al., Cyp1b1 exerts opposing effects on intestinal tumorigenesis 
via exogenous and endogenous substrates. Cancer Res, 2008. 68(18): p. 7394-
402. 
68. Paus, R., et al., Generation and cyclic remodeling of the hair follicle immune 
system in mice. J Invest Dermatol, 1998. 111(1): p. 7-18. 
69. Trempus, C.S., et al., CD34 expression by hair follicle stem cells is required for 
skin tumor development in mice. Cancer Res, 2007. 67(9): p. 4173-81. 
70. Yang, D., et al., RasGRP3, a Ras activator, contributes to signaling and the 
tumorigenic phenotype in human melanoma. Oncogene, 2011. 30(45): p. 4590-
600. 
71. Chawla, R., et al., Cooperativity of Cdk4R24C and Ras in melanoma 
development. Cell Cycle, 2010. 9(16): p. 3305-14. 
72. Chin, L., et al., Essential role for oncogenic Ras in tumour maintenance. Nature, 




73. Rane, S.G., et al., Germ line transmission of the Cdk4(R24C) mutation facilitates 
tumorigenesis and escape from cellular senescence. Mol Cell Biol, 2002. 22(2): 
p. 644-56. 
74. Krimpenfort, P., et al., Loss of p16Ink4a confers susceptibility to metastatic 
melanoma in mice. Nature, 2001. 413(6851): p. 83-6. 
75. Bastian, B.C., P.E. LeBoit, and D. Pinkel, Mutations and copy number increase of 
HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol, 2000. 
157(3): p. 967-72. 
 
 
